Literature DB >> 25802078

Heart failure: New data do not SUPPORT triple RAAS blockade.

A H Jan Danser1, Anton H van den Meiracker1.   

Abstract

The SUPPORT trial evaluated the effect of adding the angiotensin-receptor blocker olmesartan to a combination of angiotensin-converting-enzyme inhibitors and β-blockers in hypertensive patients with chronic stable heart failure. Unfortunately, this triple renin-angiotensin-aldosterone system blockade was associated with worsening of renal function and increases in cardiac events and mortality.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25802078     DOI： 10.1038/nrneph.2015.30

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  The end of dual therapy with renin-angiotensin-aldosterone system blockade?

Authors:  Dick de Zeeuw
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

2.  Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Authors:  Linda F Fried; Nicholas Emanuele; Jane H Zhang; Mary Brophy; Todd A Conner; William Duckworth; David J Leehey; Peter A McCullough; Theresa O'Connor; Paul M Palevsky; Robert F Reilly; Stephen L Seliger; Stuart R Warren; Suzanne Watnick; Peter Peduzzi; Peter Guarino
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

3.  Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE?

Authors:  Joyce E M Schilders; Haiyan Wu; Frans Boomsma; Anton H van den Meiracker; A H Jan Danser
Journal:  Cardiovasc Drugs Ther       Date:  2014-08       Impact factor: 3.727

4.  Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition.

Authors:  M Packer
Journal:  Am J Cardiol       Date:  1987-07-01       Impact factor: 2.778

5.  Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition.

Authors:  Joanna Balcarek; Bruno Sevá Pessôa; Catherine Bryson; Michel Azizi; Joël Ménard; Ingrid M Garrelds; Gerard McGeehan; Richard A Reeves; Sue G Griffith; A H Jan Danser; Richard Gregg
Journal:  Hypertension       Date:  2014-01-27       Impact factor: 10.190

Review 6.  Key developments in renin-angiotensin-aldosterone system inhibition.

Authors:  Bruno Sevá Pessôa; Nils van der Lubbe; Koen Verdonk; Anton J M Roks; Ewout J Hoorn; A H Jan Danser
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

7.  Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system.

Authors:  Jürg Nussberger; Jürgen Bohlender
Journal:  Nat Rev Cardiol       Date:  2013-03-12       Impact factor: 32.419

8.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

9.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

10.  Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.

Authors:  Yasuhiko Sakata; Nobuyuki Shiba; Jun Takahashi; Satoshi Miyata; Kotaro Nochioka; Masanobu Miura; Tsuyoshi Takada; Chiharu Saga; Tsuyoshi Shinozaki; Masafumi Sugi; Makoto Nakagawa; Nobuyo Sekiguchi; Tatsuya Komaru; Atsushi Kato; Mitsumasa Fukuchi; Eiji Nozaki; Tetsuya Hiramoto; Kanichi Inoue; Toshikazu Goto; Masatoshi Ohe; Kenji Tamaki; Setsuro Ibayashi; Nobumasa Ishide; Yukio Maruyama; Ichiro Tsuji; Hiroaki Shimokawa
Journal:  Eur Heart J       Date:  2015-01-30       Impact factor: 29.983
  10 in total
  2 in total

Review 1.  Mineralocorticoid Antagonism and Diabetic Kidney Disease.

Authors:  Yuliya Lytvyn; Lucas C Godoy; Rosalie A Scholtes; Daniël H van Raalte; David Z Cherney
Journal:  Curr Diab Rep       Date:  2019-01-23       Impact factor: 4.810

Review 2.  Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.

Authors:  Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.